TCR2 Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)
Jun 12, 2023 07:00 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:45 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:44 ET
TCR2 Therapeutics | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
Jun 1, 2023 16:43 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:41 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:41 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:40 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:39 ET
TCR2 Therapeutics | S-8 POS: S-8 POS
Jun 1, 2023 16:38 ET
TCR2 Therapeutics | 8-K: Current report
Jun 1, 2023 16:10 ET
TCR2 Therapeutics | 8-K: Current report
May 30, 2023 16:17 ET
TCR2 Therapeutics | DEFA14A: Others
May 24, 2023 16:53 ET
TCR2 Therapeutics | 8-K: Current report
May 24, 2023 16:47 ET
TCR2 Therapeutics | DEFA14A: Others
May 22, 2023 07:33 ET
TCR2 Therapeutics | 8-K: Current report
May 22, 2023 07:31 ET
TCR2 Therapeutics | 8-K: TCR 2 Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:00 ET
TCR2 Therapeutics | DEFM14A: Definitive proxy statement relating to merger or acquisition
Apr 20, 2023 16:50 ET
TCR2 Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Mar 23, 2023 07:51 ET
TCR2 Therapeutics | 8-K: TCR 2 Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
Mar 23, 2023 07:00 ET
TCR2 Therapeutics | 8-K: Current report
Mar 10, 2023 16:50 ET
No Data
No Data